Tenaya Therapeutics (TNYA) Change in Accured Expenses (2020 - 2026)

Tenaya Therapeutics' Change in Accured Expenses history runs 7 years deep, the most recent figure standing at -$2.6 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 38.57% year-over-year to -$2.6 million; the TTM figure through Mar 2026 stood at -$202000.0 (up 91.21% YoY), while the FY2025 annual figure was $532000.0, up 111.21% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$2.6 million, down from $1.1 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $2.6 million in Q4 2023, with the low at -$4.4 million in Q1 2024.
• The 5-year median for Change in Accured Expenses is $596000.0 (2024), against an average of -$14470.6.
• Peak annual rise in Change in Accured Expenses reached 184.99% in 2023, while the deepest fall reached 937.11% in 2023.
• Tenaya Therapeutics' Change in Accured Expenses stood at $2.3 million in 2022, then gained by 11.28% to $2.6 million in 2023, then sank by 72.3% to $708000.0 in 2024, then surged by 59.04% to $1.1 million in 2025, then sank by 334.19% to -$2.6 million in 2026.
• Business Quant data shows TNYA's Change in Accured Expenses at -$2.6 million in Q1 2026, $1.1 million in Q4 2025, and $918000.0 in Q3 2025.